25
Participants
Start Date
December 7, 2015
Primary Completion Date
June 30, 2017
Study Completion Date
August 30, 2017
Coagulation FVIIa (Recombinant)
A cross over design to assess the efficacy of 2 separate dose regimens (75 µg/kg and 225 µg/kg) of Coagulation Factor VIIa (Recombinant) for the treatment of bleeding episodes in hemophilia A or B patients with inhibitors to Factor VIII or Factor IX
Jimmy Everest Center for Cancer and Bleeding Disorders, Oklahoma City
UT Southwestern Medical Center at Dallas / Children's Medical Center, Dallas
University of Colorado Denver Hemophilia & Thrombosis Center, Aurora
"University Multiprofile Hospital for Active Treatment Sveti Georgi", Plovdiv
University Hospital Motol, Prague
Hematology of Department Hemophilia and Thromboses center, Tbilisi
Worthwhile Clinical Trials, Benoni
National Specialized Children's Hospital OKHMATDYT, Centre for Hemostatic Pathology (Ukraine), Kyiv
Institute of Blood Pathology and Transfusion Medicine, Lviv
LFB USA, Inc.
INDUSTRY
Laboratoire français de Fractionnement et de Biotechnologies
INDUSTRY